Stockscreener 앱 받기
1.40
11.11%
0.14
시간 외 거래:
1.41
0.01
+0.71%
전일 마감가:
$1.26
열려 있는:
$1.27
하루 거래량:
1.00M
Relative Volume:
3.32
시가총액:
$63.14M
수익:
$1.49M
순이익/손실:
$-12.27M
주가수익비율:
-4.222
EPS:
-0.3316
순현금흐름:
$-11.30M
1주 성능:
+25.00%
1개월 성능:
+64.71%
6개월 성능:
+50.01%
1년 성능:
+12.90%
1일 변동 폭
$1.26
$1.45
1주일 범위
$1.09
$1.45
52주 변동 폭
$0.7006
$1.45
Renovorx Inc Stock (RNXT) Company Profile
명칭
Renovorx Inc
전화
408-800-2649
주소
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
1.40 | 50.51M | 1.49M | -12.27M | -11.30M | -0.3316 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Renovorx Inc 주식(RNXT)의 최신 뉴스
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers - marketbeat.com
RenovoRx (NASDAQ:RNXT) Upgraded to "Hold" at Wall Street Zen - marketbeat.com
Renovorx Stock Price Forecast. Should You Buy RNXT? - StockInvest.us
H.C. Wainwright Maintains RenovoRx(RNXT.US) With Buy Rating, Maintains Target Price $3 - moomoo.com
RenovoRx Inc (NASDAQ: RNXT) Stock Price, News & Analysis - kalkine.ca
RenovoRx earnings beat by $0.02, revenue topped estimates - Investing.com Nigeria
RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ... - Yahoo Finance
RenovoRx, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
RenovoRx Q2 Earnings Call Highlights - MarketBeat
RenovoRx (RNXT) Q2 2026 Earnings Call Transcript - AOL.com
RenovoRx Q2 revenue surges 115% YoY to $909,000; raises FY26 guidance - scanx.trade
RenovoRx raises FY26 sales guidance to $3.75M-$4.25M vs $3.2M est - scanx.trade
Earnings call transcript: RenovoRx posts Q2 2026 beat, lifts guidance By Investing.com - Investing.com Canada
RenovoRx Inc reports results for the quarter ended June 30Earnings Summary - TradingView
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth - Investing News Network
RenovoRx (NASDAQ:RNXT) Posts Earnings Results, Beats Estimates By $0.02 EPS - marketbeat.com
Earnings call transcript: RenovoRx posts Q2 2026 beat, lifts guidance - Investing.com
RenovoRx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Renovorx, Inc. Increases Earnings Guidance for Full Year 2026 - marketscreener.com
RenovoRx Inc (RNXT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer - Investing News Network
RenovoRx completes enrollment in phase III pancreatic cancer trial - Investing.com
RenovoRx Inc (RNXT) Q2 2026: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer - TradingView
RenovoRx Inc (RNXT) Q2 2026: Everything You Need To Know Ahead O - GuruFocus
RenovoRx pancreatic cancer trial closes enrollment; 78 deaths occurred - Stock Titan
EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027 - Benzinga
RenovoRx Inc expected to post a loss of 7 cents a shareEarnings Preview - TradingView
RenovoRx (RNXT) Climbs 3.12% to $1.16 as Oncology Pipeline Keeps Micro-Cap in FocusNarrow Range Breakout - dars.gov.et
RenovoRx reports RenovoCath’s first clinical use in sarcoma - Medical Device Network
RenovoRx Inc (RNXT) Stock News Today - TradingKey
RenovoRx Announces First Commercial Clinical Use of RenovoCath in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors - marketscreener.com
Earnings Preview: RenovoRx to Report Financial Results Post-market on August 12 - moomoo.com
RenovoRx’s RenovoCath used in sarcoma treatment for first time By Investing.com - Investing.com Nigeria
RenovoRx’s RenovoCath used in sarcoma treatment for first time - Investing.com
RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors - The Manila Times
A Sarcoma Patient Is Receiving Local Chemotherapy via RenovoCath - Stock Titan
RenovoRx Announces First Commercial Clinical Use Of RenovoCath In Sarcoma Patient Treatment - marketscreener.com
RenovoRx (RNXT) Gains 2.4% to $1.06: Micro-Cap Biotech Presses Against ResistanceMA Crossover - dars.gov.et
RenovoRx Highlights TAMP Platform in Upcoming Oncology Webinar - TipRanks
RenovoRx to Present TAMP Platform, TIGeR-PaC Trial Update at JonesTrading Webinar Aug 13 - TradingView
RenovoRx, Inc. (NASDAQ:RNXT): Are Analysts Optimistic? - webull.com
RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th - marketscreener.com
RenovoRx Webinar to Explore Local Chemotherapy for Pancreatic Cancer - Stock Titan
RenovoRx to highlight TAMP platform and record Q1 2026 sales at webinar - scanx.trade
RNXT|RenovoRx Inc|Price:1.040|Chg%:+0.082 - TradingKey
RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET - The Manila Times
Healthy You: United Regional’s cancer center marks its first year - AOL.com
RenovoRx Inc (RNXT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
RenovoRx Inc (RNXT) Income Statement - TradingKey
Renovorx Inc (RNXT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):